Familial Adenomatous Polyposis Coli - Pipeline Insight, 2018 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Aug 24, 2018--The “Familial Adenomatous Polyposis Coli - Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
‘Familial Adenomatous Polyposis Coli - Pipeline Insight, 2018’ report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Familial Adenomatous Polyposis Coli development.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Key Topics Covered:
1. Report Introduction
2. Familial Adenomatous Polyposis Coli Overview
3. Pipeline Therapeutics
4. Comparative Analysis
5. Products in Clinical Stage
6. Products in Pre-Clinical and Discovery Stage
7. Therapeutic Assessment
8. Inactive Products
Companies MentionedCancer Prevention Pharmaceuticals Inc Marina Biotech Inc Thetis Pharmaceuticals LLC
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/l6wblv/familial?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180824005271/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Colon Cancer Drugs
INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 08/24/2018 11:09 AM/DISC: 08/24/2018 11:09 AM